At The Liver Meeting®, Bristol-Myers Squibb will present data on non-alcoholic steatohepatitis, or NASH. NASH is a condition marked by excess fat in the liver, which can lead to complications including scarring, cirrhosis, liver failure, liver transplant, or cancer. Currently, the condition is severely underdiagnosed and there are no approved treatments for NASH, which is expected to become one of the leading causes of liver transplantation and hepatocellular carcinoma (HCC) in the coming years. With a growing worldwide prevalence, the need for a better way to diagnose and treat NASH across the various stages of disease is very high. Read more about NASH.
Hear about our NASH Research below.